{"filing":{"accession_number":"0001213900-26-071738","cik":"0001723069","ticker":"TLSA","company_name":"Tiziana Life Sciences Ltd","form":"6-K","filing_date":"2026-06-25","report_date":null,"primary_document":"ea0295915-6k_tiziana.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1723069/000121390026071738/ea0295915-6k_tiziana.htm"},"events":[{"id":13685,"run_id":12154,"accession_number":"0001213900-26-071738","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This press release announces a significant clinical development milestone: the last patient has been successfully dosed in the Phase 2a INFORM-MS trial of intranasal foralumab for non-active secondary progressive multiple sclerosis, with topline data expected in late Q3/early Q4 2026. This is a material operational/clinical milestone for a clinical-stage biopharmaceutical company whose lead candidate is the subject of the trial, as it represents progress toward potential regulatory approval and commercialization of its primary therapeutic asset. The disclosure does not fit the specific event types (e.g., it is not an earnings release, M\u0026A activity, or executive change), but is clearly material to investors assessing the company's pipeline advancement and clinical execution.","company_name":"Tiziana Life Sciences Ltd","ticker":"TLSA","filing_date":"2026-06-25","form":"6-K","submitted_at":null,"items":[{"id":10896,"accession_number":"0001213900-26-071738","item_number":"EX-99.1","item_title":"ea029591501ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces a significant clinical development milestone: the last patient has been successfully dosed in the Phase 2a INFORM-MS trial of intranasal foralumab for non-active secondary progressive multiple sclerosis, with topline data expected in late Q3/early Q4 2026. This is a material operational/clinical milestone for a clinical-stage biopharmaceutical company whose lead candidate is the subject of the trial, as it represents progress toward potential regulatory approval and commercialization of its primary therapeutic asset. The disclosure does not fit the specific event types (e.g., it is not an earnings release, M\u0026A activity, or executive change), but is clearly material to investors assessing the company's pipeline advancement and clinical execution.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-25T11:01:42.651203+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":10896,"accession_number":"0001213900-26-071738","item_number":"EX-99.1","item_title":"ea029591501ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces a significant clinical development milestone: the last patient has been successfully dosed in the Phase 2a INFORM-MS trial of intranasal foralumab for non-active secondary progressive multiple sclerosis, with topline data expected in late Q3/early Q4 2026. This is a material operational/clinical milestone for a clinical-stage biopharmaceutical company whose lead candidate is the subject of the trial, as it represents progress toward potential regulatory approval and commercialization of its primary therapeutic asset. The disclosure does not fit the specific event types (e.g., it is not an earnings release, M\u0026A activity, or executive change), but is clearly material to investors assessing the company's pipeline advancement and clinical execution.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-25T11:01:42.651203+00:00","company_name":"Tiziana Life Sciences Ltd","ticker":"TLSA","filing_date":"2026-06-25"}]}